Cocrystal Pharma, Inc. Common Stock (COCP)

Price$0.96

Value ScoreD

Momentum ScoreD

Favorite Metrics

Price vs S&P 500 (26W)-16.95%

Price vs S&P 500 (4W)-33.03%

VGM Score34.30

Market Capitalization$13.30M

All Metrics

Book Value / Share (Quarterly)$0.30

P/TBV (Annual)1.61x

Indicated Dividend (Annual)$0.00

Cash Flow / Share (Quarterly)$-0.55

Price vs S&P 500 (YTD)-9.66%

Gross Margin (TTM)41.18%

Net Profit Margin (TTM)-1021.78%

EPS (TTM)$-0.73

10-Day Avg Trading Volume0.15M

EPS Excl Extra (TTM)$-0.73

EPS (Annual)$-1.80

ROI (Annual)-189.02%

Gross Margin (Annual)21.33%

Net Profit Margin (5Y Avg)-12981.54%

Cash / Share (Quarterly)$0.34

ROA (Last FY)-133.77%

EBITD / Share (TTM)$-0.74

ROE (5Y Avg)-78.39%

Operating Margin (TTM)-1047.11%

Cash Flow / Share (Annual)$-0.60

P/B Ratio3.23x

P/B Ratio (Quarterly)3.38x

Net Income / Employee (Annual)$-1,800,000

EV / Revenue (TTM)38.27x

Net Interest Coverage (TTM)-3883.00x

ROA (TTM)-97.86%

EV / EBITDA (TTM)861.02x

EPS Incl Extra (Annual)$-1.80

Current Ratio (Annual)3.68x

Quick Ratio (Quarterly)2.48x

3-Month Avg Trading Volume1.71M

52-Week Price Return-40.84%

Revenue / Employee (TTM)$22,500

Tangible BV / Share (Quarterly)$26.76

P/S Ratio (Annual)6.61x

Asset Turnover (Annual)0.04x

52-Week High$2.67

Operating Margin (5Y Avg)-26916.68%

EPS Excl Extra (Annual)$-1.80

CapEx CAGR (5Y)-45.07%

26-Week Price Return-9.03%

Quick Ratio (Annual)3.53x

13-Week Price Return-3.56%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)2.66x

Enterprise Value$8.61M

Asset Turnover (TTM)0.03x

Book Value / Share Growth (5Y)-44.72%

Revenue / Employee (Annual)$0

Pretax Margin (Annual)-480.10%

Cash / Share (Annual)$0.51

3-Month Return Std Dev115.11%

Net Income / Employee (TTM)$-882,900

ROE (Last FY)-189.02%

Net Interest Coverage (Annual)-89.72x

EPS Basic Excl Extra (Annual)$-1.80

P/FCF (TTM)6.68x

Receivables Turnover (TTM)0.00x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-0.73

Receivables Turnover (Annual)0.00x

ROI (TTM)-150.61%

P/S Ratio (TTM)59.09x

Pretax Margin (5Y Avg)-16894.02%

Revenue / Share (Annual)$0.00

Tangible BV / Share (Annual)$26.76

Price vs S&P 500 (52W)-65.21%

Year-to-Date Return-1.50%

5-Day Price Return-13.13%

EPS Normalized (Annual)$-1.80

ROA (5Y Avg)-64.43%

Net Profit Margin (Annual)-480.10%

Month-to-Date Return-13.90%

Cash Flow / Share (TTM)$-1.95

EBITD / Share (Annual)$-1.79

Operating Margin (Annual)-477.11%

LT Debt / Equity (Annual)0.01x

ROI (5Y Avg)-78.38%

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$-0.73

P/TBV (Quarterly)1.61x

P/B Ratio (Annual)2.13x

Inventory Turnover (TTM)4.43x

Pretax Margin (TTM)-1021.78%

Book Value / Share (Annual)$0.46

Price vs S&P 500 (13W)-11.82%

Beta1.47x

Revenue / Share (TTM)$0.02

ROE (TTM)-150.61%

52-Week Low$0.86

vGradeD

mGradeD

vgmGradeD

Show chart for

Earnings Surprise History

Q1 26-0.17est. -0.15

Analyst Recommendations

Feb 2026

Mar 2026

Apr 2026

May 2026

4.13

Industry Peers — Pharmaceuticals(550)

Symbol	Value Score	Growth Score	Momentum Score	Price
COCPCocrystal Pharma, Inc. Common Stock	D	—	D	$0.96
LLYEli Lilly & Co.	D	B	B	$1131.42
JNJJohnson & Johnson	D	C	B	$232.77
ABBVABBVIE INC.	D	C	C	$227.23
MRKMerck & Co., Inc.	C	C	B	$120.79
NVSNovartis AG	C	C	C	$149.16
AZNAstraZeneca PLC	D	B	C	$185.95
NVONovo-Nordisk A/S	B	B	B	$42.96
ABTAbbott Laboratories	C	C	D	$91.07
PFEPfizer Inc.	B	C	C	$26.04
BMYBristol-Myers Squibb Co.	B	C	B	$57.27

About

Cocrystal Pharma develops novel antiviral therapeutics targeting influenza, hepatitis C, and norovirus using structure-based drug design and proprietary technology platforms. The company leverages Nobel Prize-winning expertise to create first-in-class and best-in-class antiviral drugs. Its lead program, CC-31244, is an oral broad-spectrum replication inhibitor in clinical development.